scholarly journals The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series

2021 ◽  
Author(s):  
Nasikarn Angkasekwinai ◽  
Suvimol Niyomnaitham ◽  
Jaturon Sewatanon ◽  
Supaporn Phumiamorn ◽  
Kasama Sukapirom ◽  
...  
Keyword(s):  
Adverse Events ◽  
Interferon Gamma ◽  
Adenoviral Vector ◽  
Booster Dose ◽  
Booster Vaccination ◽  
Inactivated Vaccine ◽  
Booster Vaccine ◽  
Primary Series ◽  
Antibody Titres ◽  
Interferon Gamma Response

The appropriate COVID-19 booster vaccine following inactivated or adenoviral vector COVID-19 vaccination is unclear. We evaluated the safety and immunogenicity of different booster vaccines, inactivated (BBIBP-CorV), chimpanzee adenoviral vector (ChAdOx1), or mRNA (BNT162b2 at full (30 μg), or half (15 μg) dose) in healthy adults who received 2-dose primary series of either inactivated vaccine (CoronaVac) or ChAdOx1 8-12 weeks earlier. Overall, the adverse events for all booster vaccines were mild and moderate. Two weeks post-booster dose, the neutralising antibody titres against Delta variant in CoronaVac-prime and ChAdOx1-prime were highest with for 30μg-BNT162b2 (411 vs 470) and 15μg-BNT162b2 (499 vs 358); followed by ChAdOx1 (271 vs 69), and BBIBP-CorV (61.3 vs 49). BNT162b2 also induced higher interferon gamma response. Heterologous COVID-19 boosting vaccination with BNT162b2 is the most immunogenic following CoronaVac or ChAdOx1 primary series. A lower dose BNT162b2 may be used as booster in settings with limited vaccine supply.

scholarly journals The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series

2021 ◽  
Author(s):  
Nasikarn Angkasekwinai ◽  
Suvimol Niyomnaitham ◽  
Jaturon Sewatanon ◽  
Supaporn Phumiamorn ◽  
Kasama Sukapirom ◽  
...  
Keyword(s):  
Adverse Events ◽  
Interferon Gamma ◽  
Adenoviral Vector ◽  
Booster Dose ◽  
Booster Vaccination ◽  
Inactivated Vaccine ◽  
Booster Vaccine ◽  
Primary Series ◽  
Antibody Titres ◽  
Interferon Gamma Response

Abstract The appropriate COVID-19 booster vaccine following inactivated or adenoviral vector COVID-19 vaccination is unclear. We evaluated the safety and immunogenicity of different booster vaccines, inactivated (BBIBP-CorV), chimpanzee adenoviral vector (ChAdOx1), or mRNA (BNT162b2 at full (30 µg), or half (15 µg) dose) in healthy adults who received 2-dose primary series of either inactivated vaccine (CoronaVac) or ChAdOx1 8-12 weeks earlier. Overall, the adverse events for all booster vaccines were mild and moderate. Two weeks post-booster dose, the neutralising antibody titres against Delta variant in CoronaVac-prime and ChAdOx1-prime were highest with for 30µg-BNT162b2 (411 vs 470) and 15µg-BNT162b2 (499 vs 358); followed by ChAdOx1 (271 vs 69), and BBIBP-CorV (61.3 vs 49). BNT162b2 also induced higher interferon gamma response. Heterologous COVID-19 boosting vaccination with BNT162b2 is the most immunogenic following CoronaVac or ChAdOx1 primary series. A lower dose BNT162b2 may be used as booster in settings with limited vaccine supply.

scholarly journals Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine

2021 ◽  
Author(s):  
Sitthichai Kanokudom ◽  
Suvichada Assawakosri ◽  
Nungruthai Suntronwong ◽  
Chompoonut Auphimai ◽  
Pornjarim Nilyanimit ◽  
...  
Keyword(s):  
Adverse Events ◽  
Booster Dose ◽  
Viral Vector ◽  
Significant Proportion ◽  
Booster Vaccination ◽  
T Cell Response ◽  
Healthy Adults ◽  
Inactivated Vaccine ◽  
Serious Adverse Events ◽  
Vector Vaccine

AbstractThe coronavirus disease-2019 (COVID-19) pandemic has become a severe healthcare problem worldwide since the first outbreak in late December 2019. Currently, the COVID-19 vaccine has been used in many countries, but it is still unable to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection despite patients receiving full vaccination doses. Therefore, we aimed to appraise the booster effect of the different platforms of vaccines, including inactivated vaccine (BBIBP), viral vector vaccine (AZD122), and mRNA vaccine (BNT162b2) in healthy adults who received the full dose of inactivated vaccine (CoronaVac). The booster dose was safe with no serious adverse events. Moreover, the immunogenicity indicated that the booster dose with viral vector and mRNA vaccine achieved a significant proportion of Ig anti-receptor binding domain (RBD), IgG anti-RBD, and IgA anti-S1 booster response. In contrast, inactivated vaccine achieved a lower booster response than others. Consequently, the neutralization activity of vaccinated serum had a high inhibition of over 90% against SARS-CoV-2 wild-type and their variants (B.1.1.7–alpha, B.1.351–beta, and B.1.617.2–delta). In addition, IgG anti-nucleocapsid was observed only among the group that received the BBIBP booster. Our study found a significant increase in levels of interferon gamma-secreting T-cell response after the additional viral vector or mRNA booster vaccination. This study showed that administration with either viral vector (AZD1222) or mRNA (BNT162b2) boosters in individuals with a history of two doses of inactivated vaccine (CoronaVac) obtained great immunogenicity with acceptable adverse events.

scholarly journals Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 86
Author(s):  
Sitthichai Kanokudom ◽  
Suvichada Assawakosri ◽  
Nungruthai Suntronwong ◽  
Chompoonut Auphimai ◽  
Pornjarim Nilyanimit ◽  
...  
Keyword(s):  
Adverse Events ◽  
Booster Dose ◽  
Viral Vector ◽  
Significant Proportion ◽  
Booster Vaccination ◽  
T Cell Response ◽  
Healthy Adults ◽  
Inactivated Vaccine ◽  
Serious Adverse Events ◽  
Vector Vaccine

The coronavirus disease 2019 (COVID-19) pandemic has become a severe healthcare problem worldwide since the first outbreak in late December 2019. Currently, the COVID-19 vaccine has been used in many countries, but it is still unable to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, despite patients receiving full vaccination doses. Therefore, we aimed to appraise the booster effect of the different platforms of vaccines, including inactivated vaccine (BBIBP), viral vector vaccine (AZD122), and mRNA vaccine (BNT162b2), in healthy adults who received the full dose of inactivated vaccine (CoronaVac). The booster dose was safe with no serious adverse events. Moreover, the immunogenicity indicated that the booster dose with viral vector and mRNA vaccine achieved a significant proportion of Ig anti-receptor binding domain (RBD), IgG anti-RBD, and IgA anti-S1 booster response. In contrast, inactivated vaccine achieved a lower booster response than others. Consequently, the neutralization activity of vaccinated serum had a high inhibition of over 90% against SARS-CoV-2 wild-type and their variants (B.1.1.7–alpha, B.1.351–beta, and B.1.617.2–delta). In addition, IgG anti-nucleocapsid was observed only among the group that received the BBIBP booster. Our study found a significant increase in levels of IFN-ɣ secreting T-cell response after the additional viral vector or mRNA booster vaccination. This study showed that administration with either viral vector (AZD1222) or mRNA (BNT162b2) boosters in individuals with a history of two doses of inactivated vaccine (CoronaVac) obtained great immunogenicity with acceptable adverse events.

scholarly journals SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

2021 ◽  
Author(s):  
Kimberly A Kraynyak ◽  
Elliott Blackwood ◽  
Joseph Agnes ◽  
Pablo Tebas ◽  
Mary Giffear ◽  
...  
Keyword(s):  
T Cells ◽  
Adverse Events ◽  
Immune Responses ◽  
Dna Vaccine ◽  
Booster Dose ◽  
Phase 1 ◽  
The Elderly ◽  
Open Label ◽  
Serious Adverse Events ◽  
Primary Series

Background: Additional SARS-CoV-2 vaccines that are safe and effective as both primary series and booster remain urgently needed to combat the COVID-19 pandemic. Here we describe the safety and durability of the immune response from two doses of a DNA vaccine (INO-4800) targeting the full-length Spike antigen and a subsequent homologous booster dose. Methods: INO-4800 was evaluated in 120 healthy participants across three dose groups (0.5 mg, 1.0 mg and 2.0 mg), each stratified by age. INO-4800 was injected intradermally followed by electroporation at 0 and 4 weeks followed by an optional booster dose 6-10.5 months following the second dose. Results: INO-4800 was well-tolerated, with no treatment-related serious adverse events reported. Most adverse events were mild in severity and did not increase in frequency with age and subsequent dosing. A durable antibody response was observed 6 months following the second dose; a homologous booster dose significantly increased immune responses. Cytokine producing T cells and activated CD8+T cells with lytic potential were detected in the 2.0 mg dose group. Conclusion: INO-4800 was well-tolerated as a 2-dose series and as a homologous booster dose in all adults, including the elderly. These results support further development of INO-4800 as a primary series and as a booster. Keywords: SARS-CoV-2; Clinical trial; DNA Vaccine; COVID-19; Immunogenicity; Booster

scholarly journals Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice

2022 ◽  
Vol 19 (1) ◽  
Author(s):  
Shuo Song ◽  
Bing Zhou ◽  
Lin Cheng ◽  
Weilong Liu ◽  
Qing Fan ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Booster Dose ◽  
Booster Vaccination ◽  
Neutralizing Antibody ◽  
Antibody Responses ◽  
Inactivated Vaccine ◽  
Wild Type ◽  
Broadly Neutralizing Antibodies ◽  
Vaccination Strategies ◽  
Inactivated Vaccines

AbstractThe current COVID-19 pandemic caused by constantly emerging SARS-CoV-2 variants still poses a threat to public health worldwide. Effective next-generation vaccines and optimized booster vaccination strategies are urgently needed. Here, we sequentially immunized mice with a SARS-CoV-2 wild-type inactivated vaccine and a heterologous mutant RBD vaccine, and then evaluated their neutralizing antibody responses against variants including Beta, Delta, Alpha, Iota, Kappa, and A.23.1. These data showed that a third booster dose of heterologous RBD vaccine especially after two doses of inactivated vaccines significantly enhanced the GMTs of nAbs against all SARS-CoV-2 variants we tested. In addition, the WT and variants all displayed good cross-immunogenicity and might be applied in the design of booster vaccines to induce broadly neutralizing antibodies.

MULTIPLE ANTIGEN IMMUNIZATION OF INFANTS AGAINST POLIOMYELITIS, DIPHTHERIA, PERTUSSIS, AND TETANUS

PEDIATRICS ◽  
1962 ◽  
Vol 30 (5) ◽  
pp. 720-736
Author(s):  
Clarence D. Barrett ◽  
I. William McLean ◽  
Joseph G. Molner ◽  
Eugene A. Timm ◽  
Charles F. Weiss
Keyword(s):  
Booster Dose ◽  
Active Immunization ◽  
Maternal Antibody ◽  
Control Group ◽  
Tetanus Antitoxin ◽  
The Third ◽  
Multiple Antigen ◽  
Primary Series ◽  
Initial Injection ◽  
Pertussis Antigen

This study was designed to determine the earliest age in infancy at which immunization against poliomyelitis, diphtheria, tetanus, and pertussis can be started using a multiple antigen containing component antigens against all four diseases. Subjects ranged in age from 1 day old through 6 months old at time of initial injection. All were given a series of four injections of 0.5 ml of DPT-polio antigen 4 weeks apart followed by a fifth dose (0.5 ml) of the same material 6 months later. A control group received 0.5 ml of a DPT antigen at monthly intervals for their first four doses, but were given a DPT-polio injection (0.5 ml) for their fifth dose. Although it is evident that there is a progressive response in relation to age of the infant at time of initial inoculation, in respect to poliomyelitis and pertussis immunization, it was apparent that the capacity of the 3-month-old infant to respond to active immunization closely approximates that of the 6-month-old. Ninety per cent showed definite evidence of an immune response to all three poliovirus types despite extremely high levels of preprimary maternal antibody in the majority of 3-month-old infants under study. Pertussis antibody response, as measured by agglutinin titers, was as good in the 3-month-old as in the 6-month-old infants. The response in the 2-month-old infants was relatively poor at the postprimary stage but was equivalent to that of the older infants at the postbooster interval. There was no indication that response to pertussis immunization was impaired by the inclusion of pertussis antigen in the quadrivalent antigen under study. Diphtheria and tetanus antitoxin titers were excellent regardless of age at initial inoculation. The results indicate that four doses of DPT-polio combined antigen given at monthly intervals will overcome the interference of high levels of maternal antibody in respect to poliomyelitis immunization and that the primary series of injections may be started as early as the third month of life. It is important, however, that this primary series of inoculations be followed by a booster dose of the same antigen preparation in about 6 months in order to reinforce the basic immunity.

Sign in / Sign up

Export Citation Format

Share Document